4.8 Article

DockCoV2: a drug database against SARS-CoV-2

Journal

NUCLEIC ACIDS RESEARCH
Volume 49, Issue D1, Pages D1152-D1159

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/nar/gkaa861

Keywords

-

Funding

  1. Ministry of Science and Technology, Taiwan [MOST 108-2221-E-002-079-MY3, MOST 109-2221-E-002-161-MY3, MOST109-2327-B-002-009, MOST 109-3114-Y-001-001]
  2. Higher Education Sprout Project [NTU-109L8837A]

Ask authors/readers for more resources

The current global health crisis due to COVID-19 has prompted researchers to develop DockCoV2, a drug database that focuses on predicting the binding affinity of drugs with key proteins of SARS-CoV-2 in order to expedite the discovery of potential treatments.
The current state of the COVID-19 pandemic is a global health crisis. To fight the novel coronavirus, one of the best-known ways is to block enzymes essential for virus replication. Currently, we know that the SARS-CoV-2 virus encodes about 29 proteins such as spike protein, 3C-like protease (3CLpro), RNA-dependent RNA polymerase (RdRp), Papainlike protease (PLpro), and nucleocapsid (N) protein. SARS-CoV-2 uses human angiotensin-converting enzyme 2 (ACE2) for viral entry and transmembrane serine protease family member II (TMPRSS2) for spike protein priming. Thus in order to speed up the discovery of potential drugs, we develop DockCoV2, a drug database for SARS-CoV-2. DockCoV2 focuses on predicting the binding affinity of FDA-approved and Taiwan National Health Insurance (NHI) drugs with the seven proteins mentioned above. This database contains a total of 3,109 drugs. DockCoV2 is easy to use and search against, is well cross-linked to external databases, and provides the state-of-the-art prediction results in one site. Users can download their drug-protein docking data of interest and examine additional drug-related information on Dock-CoV2. Furthermore, DockCoV2 provides experimental information to help users understand which drugs have already been reported to be effective against MERS or SARS-CoV.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available